The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett’s Esophagus
Effect estimates of TSP-9 performance demonstrate that the test provides risk stratification for BE patients. The TSP-9 test can provide clinically impactful results to enable escalation of care for high-risk patients or to identify low-risk patients who can be safely managed with routine surveillance.
Authors
- John C. Lipham (ORCID: https://orcid.org/0000-0002-6203-5263)
- Luke Randall Putnam (ORCID: https://orcid.org/0000-0001-7455-0919)
- Ivo Ditah
- Cadman L. Leggett (ORCID: https://orcid.org/0000-0002-0495-3795)
- Amrit K. Kamboj (ORCID: https://orcid.org/0000-0002-8296-1029)
- Sarah L. Sokol-Borrelli
- Caitlin C. Houghton
Institutions
- Regions Hospital (US)
- Cedars-Sinai Medical Center (US)
- Keck Hospital of USC (US)
- Mayo Clinic in Arizona (US)
- Knopp Biosciences (United States) (US)
- System Biosciences (United States) (US)
- Mayo Clinic in Florida (US)
- HealthPartners (US)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1097/mcg.0000000000002255
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01